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Abstract
Purpose: To investigate the promoter methylation status at selected loci which encode for key proteins involved in
apoptosis, DNA repair, cell cycle control and progression in urothelial cell carcinoma of bladder and compare the
findings from tissue samples with that of plasma.
Methods: Total genomic DNA was isolated from 43 non-muscle invasive (low grade) and 33 muscle invasive (high
grade) urothelial bladder cancer samples along with 10 control cases of normal bladder mucosa. Promoter methylation
status was investigated for RASSF1A, APC, MGMT, CDKN2A and CDKN2B genes using real-time methylation-specific
PCR with SYBR® green. Plasma samples from 16 patients with muscle invasive high grade bladder cancer were
also subjected to similar analyses.
Results: Promoter hypermethylation was frequently observed in RASSF1A, APC and MGMT gene promoters
(p-value < 0.001). The methylation was more prominent in the muscle invasive high grade bladder cancer when
compared to non-muscle invasive low grade group (p-value < 0.001) and normal bladder mucosa (p-value < 0.05).
The RNA expression of RASSF1A, APC and MGMT was also found to be decreased in the muscle-invasive high
grade bladder cancer when compared to the non muscle invasive low grade group (p-value < 0.05). RASSF1A,
MGMT and CDKN2A showed comparable results when data from 16 plasma samples was compared to the
corresponding tissue samples.
Conclusion: Our results suggest that epigenetic silencing of RASSF1A, APC and MGMT genes is strongly associated
with invasive high grade urothelial bladder cancer. Thus, status of promoter methylation has the potential to serve as
valuable tool for assessing aggressiveness of urothelial cell carcinoma of bladder.
Keywords: Promoter methylation; Tumor suppressor genes; Paraffin embedded tissue; Plasma; Urothelial cell
carcinoma of bladder

Background
Urinary bladder cancer represents the second most frequent urologic cancer worldwide which accounts for
3.3% of newly diagnosed cancer cases and 2.1% of cancer
deaths. Globally, the incidence of bladder cancer is highest among North American and Western European populations (<16.2 per 100,000); in comparison Eastern
* Correspondence: farhat.abbas@aku.edu
4
Department of Surgery, Aga Khan University, Stadium Road, Karachi 74800,
Pakistan
Full list of author information is available at the end of the article

Europe & Asian countries have relatively lower rates
(<1.7 per 100,000). Alarmingly, Pakistan carries a heavy
burden of disease among all South Central Asian countries with mortality rate of 3.8 and 1.1 per 100,000 in
males and females, respectively (IARC 2013).
At present, cystoscopy followed by histological examination serve as the gold standard for making the initial
diagnosis and monitoring progression of bladder tumors.
Although cystoscopy provides valuable information regarding tumor status, it involves an invasive procedure
which is not very cost effective. In view of this, there is a
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dire need to identify robust genetic and/or epigenetic
markers that can serve as reliable indicators of disease.
Over the past two decades a number of biomarkers such
as nuclear matrix protein 22 (NMP22), fibrin degradation
product (Fibrin/FDP), bladder tumor antigen (BTA), high
molecular weight carcinoembryonic antigen and mucin
have been identified and approved by FDA for monitoring
and screening of bladder cancers but initial enthusiasm
for their clinical utility waned quickly because each of
them lacked specificity, reproducibility as well as sensitivity (Ludwig and Weinstein 2005).
DNA methylation negatively influences transcription
and plays a pivotal role in shaping the epigenome to ascertain accurate temporal and spatial expression of genes
during development. It occurs in distinct regions of promoters where the density of the dinucleotide CpG is
higher than would be expected in random sequence.
These so called “CpG islands” are found in over 60% of
the human genes. The process of converting an unmodified CpG into one which is methylated at the C5 position of cytosine is catalyzed by DNA methyltransferases
(DNMT). DNMT1 uses hemi-methylated CpG resides as
substrate and fully methylates them. In contrast, DNMT3
is capable of methylating unmodified CpG dinucleotides
de novo. Since DNA hypermethylation serves as a
powerful mechanism that turns off gene transcription
any unprogrammed changes in the epigenome – be it
hypermethylation of a tumor suppressor genes (TSGs)
or demethylation of oncogenes – are likely to culminate
in a disease state. Indeed, silencing of tumor suppressor
genes due to CpG hypermethylation has been well documented in different types of cancers. In bladder cancer,
expression and function of a number of TSGs including
PTCH, TSC1, RB1, PTEN, p53, DAPK, FHIT, CDH1,
CDKN2B, CDKN2A, APC, RASSF1A and MGMT are
known to be impacted either by physical changes in the
sequence of DNA or by un-programmed DNA methylation (Cairns 2007; Knowles 2007).
In this study we have investigated the DNA methylation status of a panel of tumor suppressor genes that include RASSF1A, APC, MGMT, CDKN2A and CDKN2B
using formalin fixed paraffin embedded (FFPE) biopsies
obtained from individuals suffering from non- muscle
invasive and muscle invasive urothelial cell carcinoma of
bladder from Pakistan. Normal bladder mucosa/benign
urologic disease samples were used as controls. These
genes were selected because their respective products influence cell cycle control, apoptosis and DNA repair,
and because they have been found to be epigenetically
silenced in many human neoplasms.

invasive tumors (pTa-T1) and 33 muscle invasive tumors
(≥pT2). Transitional cell carcinoma was low grade
(including papillary urothelial neoplasm of low malignant potential) in 43 patients and high grade in 33
patients. The median age of patients was 64 years in
non-invasive low grade cancer group and 61 years in invasive high grade bladder cancer. Methylation analyses
were also carried out in 10 patients with benign urologic
disease as control group with a median age of 49 years.
Details of the individuals whose tissues were used in this
study are listed in Table 1.
Genomic DNA from the 76 FFPE diseased as well as
10 control tissues was isolated, modified by bisulfite
reagent and subsequently used as template for carrying
out methylation-specific real-time PCR analysis using
pairs of gene-specific primer sets. This revealed that
the prevalence of promoter hypermethylation in all
five tumor suppressor genes was higher in the muscle
invasive high grade urothelial bladder cancer as compared to the non-muscle invasive low grade group
(Table 2).
Out of the five tumor suppressor genes studied in the
normal bladder mucosa, muscle invasive and non-muscle
invasive urothelial bladder cancer, the promoter hypermethylation at RASSF1A, APC and MGMT was statistically
significant (p < 0.001; Table 3). Unexpectedly, RASSF1A
promoter was also found to be hypermethylated in 5
(2 females and 3 males) out of 10 normal bladder mucosa samples.

Results
Our study included 76 patients with transitional cell carcinoma of bladder from which 43 were non-muscle

(pTa: Non-invasive papillary carcinoma, pT1: Tumor invades sub epithelial
connective tissue, pT2: Tumor invades muscle, pT3: Tumor invades perivesical
tissue, pT4: Tumor invades any of the following: prostate, uterus, vagina, pelvic
wall, abdominal wall).

Comparison of normalized index of methylation

Normalized index of methylation (NIM) for all the
tumor suppressor genes in the cancer and control group
was calculated. The NIM serves as an index of the percentage of bisulfite converted input copies of DNA that
Table 1 Clinicopathological parameters of normal and
bladder Cancer FFPE samples
Parameter

Number of patients

Low grade
urothelial
cancer

High grade
urothelial
cancer

Normal
bladder
mucosa

43

33

10

Males

37(86%)

26(78%)

05

Females

06(14%)

07(21%)

05

64(50-73)

61(53-68)

49(40-59)

Age
Median (Inter-quartile range)
Pathologic stage
pTa-pT1
≥pT2

43
33
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Table 2 Frequency of hypermethylation of tumor
suppressor gene loci in urothelial bladder cancer samples
Tumor
suppressor
gene

Low grade urothelial
carcinoma of urinary
bladder (TCC) n = 43

High grade urothelial
carcinoma of urinary
bladder (TCC) n = 33

RASSF1A

49% (21/43)

82% (27/33)

APC

51% (22/43)

97% (32/33)

MGMT

93% (41/43)

94% (31/33)

CDKN2A

19% (8/43)

24% (8/33)

CDKN2B

37% (16/43)

57% (19/33)

Change in mRNA expression

are fully methylated at the primer binding sites. However, it is important to note that the NIM maybe >1 if
the copies of Actin are deleted relative to the gene of
interest, or copies of the gene of interest are gained relative to Actin in any given sample.
When the mean normalized index of methylation of
the genes was compared between non- muscle invasive
low grade and muscle invasive high grade urothelial
bladder cancer, the degree of hypermethylation was more
prominent in the muscle invasive high grade group for
RASSF1A, APC and MGMT (p < 0.001). However, only
APC and MGMT showed significance (p < 0.001) in the
muscle invasive high grade bladder cancer when it was
compared with the normal bladder mucosa (Figure 1).
Table 3 Normalized index of methylation (NIM)% and
corresponding p-values
RASSF1A

APC

MGMT

CDKN2A CDKN2B

Invasive high grade
urothelial bladder
cancer (n = 33)
Mean

40

6.1

9

0.09

0.58

Range

0-270

0-50

0-96

0-2

0-6

Mean

2

2

2.3

0.4

0.1

Range

0-49

0-43

0-41

0-8

0-2

Mean

2

0

0

1

2

Range

0-12

0

0-4

0-16

0-1

0.748

0.114

Non-invasive low
grade urothelial
bladder cancer
(n = 43)

Normal bladder
(n = 10)

*p-value

<0.001

<0.001 <0.001

Plasma samples
(n = 16)
Mean

24.9

0.035

16.2

1.5

5.9

Range

3-125

0-4.4

0.1111.7

0-16.3

0.1-18.9

**p-value

0.539

<0.001

0.524

0.215

<0.01

*Kruskal Wallis Test **Paired T-Test (p-value<0.01).

Interestingly, none of the tumor suppressor genes reached
statistical significance when NIM was compared between
normal bladder mucosa and non-muscle invasive low
grade bladder cancer (Table 4).

NIM was found to be higher for RASSF1A, APC and
MGMT in muscle invasive high grade urothelial bladder
cancer as compared to the non muscle invasive low
grade cancer. In order to determine any difference in the
gene expression between the two groups, total RNA was
extracted from formalin fixed and paraffin embedded
samples, was reverse transcribed and amplified using
specific primers. The mRNA expression of RASSF1A,
APC and MGMT was found to be decreased in the
muscle invasive high grade urothelial cell carcinoma of
bladder as compared to the non- muscle invasive low
grade group (Figure 2), and this finding was statistically
significant (p-value < 0.05) when Wilcoxon signed rank
test was applied.
Association between biopsy and plasma samples

In the next step, to assess whether there is an association
between the promoter methylation patterns detected in
tissue samples with those in blood samples, promoter
hypermethylation at the tumor suppressor genes was also
determined in sixteen plasma samples from patients with
invasive high grade urothelial bladder cancer. When the
results were statistically analyzed using paired-T test,
RASSF1A, MGMT and CDKN2A showed comparable results in the cancer tissue and plasma samples. Whereas,
APC (p < 0.01) and CDKN2B (p < 0.05) showed significant
difference between the two.
Survival analysis

By Kaplan-Meier analysis, the methylation status of
genes did not show any significance in correlation with
the recurrence-free interval. However, a pattern was observed with worse recurrence free survival in methylation positive urothelial cell carcinoma of bladder. When
the overall survival was correlated with the methylation
status of candidate tumor suppressor genes, it was found
to be significantly shorter in patients with RASSF1A and
APC methylation positive tumor (Figure 3).

Discussion
In the present study, we have investigated the promoter
methylation status of candidate tumor suppressor genes
namely RASSF1A, APC, MGMT, CDKN2A and CDKN2B
in normal bladder mucosa, invasive high grade and noninvasive low grade urothelial bladder cancer using formalin fixed paraffin embedded tissue and plasma samples.
Our results demonstrate that the prevalence of promoter methylation was higher in invasive high grade
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Figure 1 Comparison of Normalized index of methylation (NIM) for the tumor suppressor genes. a Between normal bladder mucosa (NB) and
muscle invasive high grade (IHG) urothelial bladder cancer (*p-value for APC and MGMT was <0.001) b Between muscle invasive high grade (IHG) and
non-muscle invasive low grade (NILG) urothelial bladder cancer (*p-value for RASSF1A, APC and MGMT was <0.001 each-*Mann–Whitney-U Test).

urothelial bladder cancer as compared to the noninvasive low grade. Out of the five genes studied the
prevalence of hypermethylation was 82%, 97% and 94%
for RASSF1A, APC and MGMT, respectively. Interestingly,
the findings from formalin fixed paraffin embedded samples were comparable to the plasma samples of invasive
high grade bladder cancer patients for CDKN2A, MGMT
and RASSF1A.
The RASSF1 (Ras association domain family 1) family
represents a class of Ras effector proteins that have tumor
suppressor properties. RASSF1A acts as a putative tumor
suppressor gene located on 3p21 and may serve as an effector that mediates the apoptotic effects by binding Ras
in a guanosine triphosphate-dependent manner (Hesson
et al. 2007). Studies have shown that as compared to the
classic mutations, promoter hypermethylation serve as
major mechanism of gene silencing in RASSF1A.
Promoter methylation induced silencing of RASSF1A
has been found to be associated with multiple human cancers (Bhagat et al. 2012; Jiang et al. 2012; Koutsimpelas
et al. 2012; Munoz et al. 2012; Jeronimo et al. 2004). Previous studies have shown that RASSF1A methylation was
detectable in body fluids including plasma, nipple aspirate,
sputum, urine and bronchoalveolar lavage (Dulaimi et al.
2004; Krassenstein et al. 2004; Topaloglu et al. 2004;
Belinsky et al. 2005; Hoque et al. 2006).

Table 4 Comparison of NIM and corresponding p-values
**NB vs. NILG
NB vs. IHG
NILG vs. IHG

RASSF1A

APC

MGMT

CDKN2A

CDKN2B

0.03

0.04

1.00

0.61

0.17

0.04

<0.001*

<0.01*

0.58

1.00

<0.001*

<0.001*

<0.001*

0.72

0.05

*Mann–Whitney-U Test (p-value < 0.01, after correction for multiple testing);
**NB = Normal bladder mucosa, sNILG = Non-muscle invasive low grade
urothelial bladder cancer; IHG = Muscle invasive high grade urothelial
bladder cancer).

In bladder cancer, RASSF1A methylation has been
linked to high grade bladder tumors and poor prognosis
(Gao et al. 2012; Meng et al. 2012; Maruyama et al.
2001). We also found RASSF1A methylation in five out
of ten normal bladder mucosa samples, which is in
agreement with other studies. But this finding would
raise questions about its utility as a biomarker due to
low specificity; hence, studies on larger sample size are
needed to address this issue.
Mutations in APC (Adenomatous polyposis coli) gene
are known to be associated with Familial adenomatous
polyposis coli and colorectal cancer. APC protein acts
as a negative regulator of WNT/β-catenin signaling
pathway as it promotes the proteolytic degradation of
β-catenin in Wnt signaling pathway. It also plays a role
in cell migration and adhesion, apoptosis and transcriptional activation (Klaus and Birchmeier 2008).
As an interesting finding hypermethylation of APC
gene promoter was more prominent in invasive high
grade urothelial bladder cancer as compared to noninvasive low grade one which is also in line with the previous
studies correlating APC methylation with tumor grade,
stage and muscle invasion (Berrada et al. 2012; Hoque
et al. 2006).
MGMT gene encodes an enzyme called O-6-Methylguanine DNA methyltransferase which removes a carcinogenic DNA lesion, O (6)-alkyl-guanine. The promoter
methylation at MGMT has been reported in many human cancers but found to be less frequent in bladder
cancer. (Bhagat et al. 2012; Koutsimpelas et al. 2012;
Liu et al. 2011; Yates et al. 2007) Our study shows a
prominent MGMT hypermethylation in the invasive
high grade bladder cancer as well as the non-invasive
low grade cancer and the findings were correlated in
the plasma samples. However, the the methylation
index was higher in the invasive high grade urothelial
bladder cancer.
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NILG

IHG

Figure 2 RNA Expression of tumor suppressor genes RASSF1A, APC and MGMT in non muscle invasive low grade (NILG) and muscle
invasive high grade (IHG) urothelial cell carcinoma of bladder. Total RNA was extracted from formalin fixed and paraffin embedded samples,
was reverse transcribed and amplified using primers against RASSF1a, APC and MGMT to determine any difference in the expression of RNA. (p-value
for RASSF1A, APC and MGMT was <0.05 each-when Wilcoxon signed rank test was applied).

Impaired regulation of cell cycle control is an important event in tumorigenesis. The regulation of cell cycle
involves multiple check points including cyclins, cyclin
dependent kinase enzymes and cyclin dependent kinase
inhibitors. Cyclin dependent kinase inhibitor 2A and 2B,
p16 and p15 respectively, act as negative regulators of
cell cycle progression and thus are potential tumor suppressors p16/cyclin-dependent kinase inhibitor 2A (CDKN2A)
encodes splice variants and is involved in sequestering
MDM2 so p53 gets stabilized. It inhibits enzyme CDK4
kinase, hence inhibits progression of cell cycle from G1
phase.
Studies on CDKN2A/p16 promoter methylation in
bladder cancer have shown varying results reporting the
frequency of methylation ranging from 7-60% (Chan,
Chan et al. 2002; Dominguez et al. 2002; Chang et al.
2003; Catto et al. 2005). In our study, the overall methylation frequency for CDKN2A/p16 was low in both invasive high grade (24%) and non-invasive low grade (19%)

urothelial bladder cancer with a very low normalized
index of methylation. However, the results were found
to be analogous when the CDKN2A/p16 methylation
found in paraffin embedded samples was compared to
the plasma samples.
Like p16, p15/cyclin-dependent kinase inhibitor 2B
(CDKN2B) also encodes a cyclin dependent kinase inhibitor
which inhibits CDK4 or CDK6 kinases and prevents the
cell cycle progression from G1 phase. Significant promoter
hypermethylation has been reported for both CDKN2A and
CDKN2B in cervical cancer patients of North Indian origin
(Jha et al. 2012).
Promoter methylation at CDKN2B/p15 is not frequent
in bladder cancer, as previous studies have reported a
methylation frequency ranging from 0-13% (Le Frere-Belda
et al. 2001). Our results have shown that CDKN2B promoter methylation was slightly higher than CDKN2A but
the findings of CDKN2B methylation from paraffin embedded sample were not comparable to the plasma samples.

Figure 3 Association of patients’ survival and promoter methylation status by Kaplan-Meier method. a survival curves by methylation
status of RASSF1A (Number of censored cases with and without methylation were 17 and 14, respectively) b survival curves by methylation status
of APC (Number of censored cases with and without methylation were 19 and 12, respectively).
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Conclusion
To summarize, our study demonstrates that promoter
hypermethylation in tumor suppressor genes plays an
important role in bladder cancer development and progression which is evident from the finding that methylation of some tumor suppressor genes associates well
with tumor grade, invasiveness and patient’s survival.
Although much has been published in this regard but
data from developing world is lacking. This study, though
involving some preliminary results on plasma samples, is
the first of its kind on a south central Asian population. If
the findings are validated using larger number of samples,
it could serve as a rapid tool for assessing aggressiveness
of bladder cancer in the Pakistani population.
However, to select an ideal gene panel that is specific
for bladder cancer still remains a critical issue for designing the most useful panel of epigenetic biomarkers
that can come into clinical practice for an early diagnosis
or monitoring the progression of disease.
Methods
Samples

This study was approved by the Ethical Review Committee of The Aga Khan University and all samples used or
collected followed the approved protocol. Source of
bladder cancer tissues were the 76 formalin fixed paraffin embedded blocks prepared from tissue obtained from
patients who underwent cystoscopy and/or transurethral
resection of bladder tumor (TURBT) during 2008-2012.
Blocks with >70% cancerous tissue were selected after
histological examination of slides and categorized into
non-muscle invasive low grade and muscle invasive high
grade urothelial bladder cancer. In addition, 10 blocks of
benign bladder mucosa with no evidence of malignancy
were obtained from patients who underwent cystoscopy
and bladder biopsy during 2007-2012 for different urinary complaints; these served as control (Figure 4).
Approximately 5 ml of venous blood sample was also
collected from 10 age matched healthy individuals
and 16 patients with invasive high grade urothelial
bladder cancer who underwent cystoscopy and/or
TURBT in 2012.

DNA extraction from FFPE samples
DNA was extracted from formalin-fixed paraffin embedded (FFPE) blocks using QIAamp® DNA FFPE tissue kit
(Qiagen). Briefly, around 5-7 sections of 5-10 μm thickness were cut from block with microtome (Leica Inc.)
and collected in an eppendorf tube. Tissue sections were
deparaffinized by adding 1 ml xylene to the sample, tube
was vortexed vigorously and then centrifuged at 14,000 rpm
for 2 minutes at room temperature. Supernatant was
removed and 1 ml of ethanol was added (to remove residual xylene from the sample), mixed by vortexing and
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centrifuged at 14,000 rpm for 2 minutes at room
temperature. Supernatant was removed and the pellet
air dried at 37°C until residual ethanol had evaporated.
Tissue samples were homogenized in the Buffer ATL
(180 μl) provided in the kit. Homogenized tissue samples
were subjected to digestion by adding 20 μl proteinase-K
at a concentration of 10 mg/ml, mixed by vortexing and
tube incubated at 56°C for 1 hour to ensure complete tissue lysis. To reverse the formaldehyde modification of nucleic acids, tubes were incubated at 90°C for 1 hour. DNA
was placed in a spin column, washed in situ, and eluted in
50 μl TE buffer. This DNA was quantitated by Nanodrop
ND-1000 Spectrophotometer (Thermo Scientific). About
1-2 μg of DNA with A260:A280 > 1.8 was subjected to bisulfite modification using EpiTect® Bisulfite kit (Qiagen)
following manufacturer’s protocol.
DNA extraction from plasma

DNA was extracted from plasma samples using QIAamp®
DNA Blood Mini kit (Qiagen) following manufacturer’s
instructions. Briefly, 200 μl of plasma sample was added
to a microcentrifuge tube containing 20 μl Proteinase K
and was mixed thoroughly by pipetting. Lysis buffer AL
(200 μl) was added to this mixture and incubated at 56°C
for 10 minutes after thorough vortexing. The tubes were
centrifuged briefly, and absolute ethanol (200 μl) was
added to the sample, pulse vortexed for 15 seconds and
centrifuged briefly. The entire mixture was applied to
the QIAamp Mini spin column in a 2 ml collection
tube (provided in the kit). The columns were centrifuged at 8000 rpm for 1 minute, flow through was discarded and columns were placed on to new collection
tubes. Two washings were done with 500 μl buffer
AW1 and AW2, filtrate was discarded and columns
were placed on new collection tubes. QIAamp Mini
spin columns were placed in a new 1.5 ml microcentrifuge tube, 200 μl buffer AE was added to the spin column and was incubated at room temperature (15-25°C)
for 5 minutes, and then centrifuged at 8000 rpm for
1 minute to elute the DNA. The DNA samples were
quantitated by Nanodrop ND-1000 Spectrophotometer
(Thermo Scientific) and only samples with good concentration and nucleic acid/protein ratio > 1.8 were
processed further to bisulfite conversion.
Bisulfite conversion

Sodium bisulfite conversion of genomic DNA extracted
from paraffin embedded blocks and plasma samples were
carried out using EpiTect Bisulfite kit (Qiagen) as per
manufacturer’s protocol. Bisulfite reactions were carried
out in 200 μl PCR tubes on Mastercycler (Eppendorf)
using the following conditions: 95°C for 5 min, 60°C for
25 min, 95°C for 5 min, 60°C for 85 min, 95°C for 5 min,
and 60°C for 59 min.
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Figure 4 H & E Staining. a Normal urothelium, b and c Non muscle invasive and low grade Urothelial cell carcinoma of bladder 10X and 20X
respectively, d High grade Urothelial cell carcinoma of bladder, e Muscle invasion in high grade Urothelial cell carcinoma of bladder.

Subsequently, purification of DNA was carried out by
adding 310 μl of freshly prepared Buffer BL containing
10 μg/ml of carrier RNA and vortexing. Then 250 μl of
ethanol was added and vortexed for 15 seconds. The
entire mixture was transferred to EpiTect spin column
and centrifuged at 14,000 rpm for 1 minute. Then 500 μl
of Buffer BD (desulfonation buffer) was added and column was incubated for 15 min at room temperature.
After washing by 500 μl of Buffer BW, DNA was eluted
by addition of 20 μl of buffer EB and centrifuged at
14,000 rpm for 1 minute. Bisulfite converted DNA was
stored at -20°C until use.
Methylation-specific PCR

Promoter methylation analysis at RASSF1A, APC, MGMT,
CDKN2A and CDKN2B was carried out with bisulfite converted DNA on Chromo-4 cycler (Bio-Rad) with Maxima

SYBR Green Master mix (Fermentas) as the intercalating dye. Primer sequences are given in Additional file 1:
Table S1. The following thermal cycling conditions
were used: 95°C for 10 min, followed by 44 cycles of
95°C for 15 sec, and 60°C for 1 min. Melting curve was
obtained from 65°C to 90°C.
Approximately 10 ng of methylated and bisulfite converted human DNA (Epitect® Control DNA, Qiagen) was
used as control in which, complete in vitro methylation of
the control DNA was achieved using Sss1 methylase and
Bisulfite conversion of control DNA was achieved using
the EpiTect Bisulfite kit. The housekeeping gene β-actin
was used as the normalization control.
All samples were run in duplicate. Data was generated
on Opticon Monitor 3 software (Bio-Rad). The software
GENEX 5 was used to analyze the results. Samples with
Ct value <35 were considered as positive.
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Normalized index of methylation

The Ct value of each gene was related to its copy number and Normalized index of methylation (NIM) was
calculated as the ratio of copy number of gene of interest in the sample to that of control and both were normalized to the copy number of housekeeping gene i.e.;
NIM ¼



 



GeneSample =ðGeneControl Þ = ActinSample =ðActinControl Þ

Where, (Gene Sample) is the number of fully methylated
copies of the gene of interest in a given sample, (Gene
Control) is the number of fully methylated copies of the
gene of interest in the SssI universally methylated control DNA, (Actin Sample) is the number of Actin copies in
a given sample, and (Actin Control) is the number of Actin
copies in the SssI universally methylated DNA.
RNA extraction from FFPE samples

RNA was extracted from paraffin embedded blocks
using RNeasy® FFPE kit (Qiagen) according to manufacturer’s protocol. Briefly 5-10 sections of 5 μm thickness
were cut from the paraffin embedded blocks with microtome (Leica Inc.). After paraffin removal with xylene,
samples were processed under denaturing conditions
with proteinase K and incubated at 80°C for 15 minutes
to reverse formalin cross-links. Genomic DNA was removed by passing the lysate through gDNA elimination
spin column provided in the kit. Sample was placed in a
spin column, washed in situ, and eluted in 30 μl RNase
free water. Approximately 1 μg of RNA with A260/A280 ~ 2
was subjected to reverse transcription using Quantiscript
reverse transcription kit (Qiagen) following manufacturer’s
protocol. RNA expression of RASSF1A, APC and MGMT
was determined by real time-PCR (Bio-Rad) using SYBR
green using specific primers. Primer sequences are given
in Additional file 2: Table S2.
Statistical analysis

Statistical analysis was carried out using SPSS (version 19).
The statistical tests used to evaluate the difference in the
promoter methylation of candidate genes among normal
bladder mucosa, non-invasive and invasive urothelial bladder cancer were Kruskal-Wallis and Mann–Whitney-U.
Difference in the RNA expression between muscle invasive (high grade) and non muscle invasive (low grade)
urothelial bladder cancer was evaluated using Wilcoxon
signed rank test. Paired T-test was used to evaluate if
there is any difference in the findings of promoter
methylation status using paraffin embedded blocks
versus blood samples. All p-values <0.01 were considered statistically significant. The association between
the promoter methylation status and patients’ survival
(Overall and recurrence free) was studied applying
Kaplan-Meier survival plots.
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Additional files
Additional file 1: Table S1. Primer sequences for the tumor suppressor
genes included in the study (Xu et al. 2004).
Additional file 2: Table S2. Primer Sequences for RASSF1A, APC and
MGMT real time RT-PCR analysis.
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